Roth Capital Reaffirms Actinium Pharma (ATNM) at 'Buy'; Says Starting Actimab-A Phase 2 is 'Important Step'
Tweet Send to a Friend
Roth Capital affirms Actinium Pharmaceuticals (NYSE: ATNM) with a Buy rating and $5 price target after the company initiated a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
